We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
Eli Lilly (LLY - Free Report) closed the most recent trading day at $276.22, moving -0.37% from the previous trading session. This change lagged the S&P 500's daily loss of 0.26%. At the same time, the Dow lost 0.16%, and the tech-heavy Nasdaq lost 0.04%.
Coming into today, shares of the drugmaker had gained 11.85% in the past month. In that same time, the Medical sector gained 5.77%, while the S&P 500 gained 4.82%.
Investors will be hoping for strength from Eli Lilly as it approaches its next earnings release. In that report, analysts expect Eli Lilly to post earnings of $2.50 per share. This would mark a year-over-year decline of 9.09%. Meanwhile, our latest consensus estimate is calling for revenue of $7.56 billion, up 1.61% from the prior-year quarter.
LLY's full-year Zacks Consensus Estimates are calling for earnings of $8.18 per share and revenue of $28.29 billion. These results would represent year-over-year changes of +3.15% and +15.3%, respectively.
Investors should also note any recent changes to analyst estimates for Eli Lilly. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 1.79% higher within the past month. Eli Lilly is currently sporting a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Eli Lilly has a Forward P/E ratio of 33.9 right now. This represents a premium compared to its industry's average Forward P/E of 13.83.
Investors should also note that LLY has a PEG ratio of 2.13 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.11 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 167, which puts it in the bottom 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow LLY in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know
Eli Lilly (LLY - Free Report) closed the most recent trading day at $276.22, moving -0.37% from the previous trading session. This change lagged the S&P 500's daily loss of 0.26%. At the same time, the Dow lost 0.16%, and the tech-heavy Nasdaq lost 0.04%.
Coming into today, shares of the drugmaker had gained 11.85% in the past month. In that same time, the Medical sector gained 5.77%, while the S&P 500 gained 4.82%.
Investors will be hoping for strength from Eli Lilly as it approaches its next earnings release. In that report, analysts expect Eli Lilly to post earnings of $2.50 per share. This would mark a year-over-year decline of 9.09%. Meanwhile, our latest consensus estimate is calling for revenue of $7.56 billion, up 1.61% from the prior-year quarter.
LLY's full-year Zacks Consensus Estimates are calling for earnings of $8.18 per share and revenue of $28.29 billion. These results would represent year-over-year changes of +3.15% and +15.3%, respectively.
Investors should also note any recent changes to analyst estimates for Eli Lilly. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 1.79% higher within the past month. Eli Lilly is currently sporting a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Eli Lilly has a Forward P/E ratio of 33.9 right now. This represents a premium compared to its industry's average Forward P/E of 13.83.
Investors should also note that LLY has a PEG ratio of 2.13 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.11 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 167, which puts it in the bottom 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow LLY in the coming trading sessions, be sure to utilize Zacks.com.